Profile data is unavailable for this security.
About the company
Hikma Pharmaceuticals PLC is a pharmaceutical company. The principal activities of the Company are the development, manufacture and marketing of a range of generic, branded and in-licensed pharmaceutical products. The Company operates through three segments: Injectables, Branded and Generics. The Injectables segment supplies hospitals across its markets with generic injectable products, supported by its manufacturing facilities in the United States, Europe and Middle East/North Africa (MENA). It is also engaged in the finished dosage form (FDF) business and has a manufacturing facility in Cleveland, Ohio. The Branded segment supplies branded generics and in-licensed patented products from its local manufacturing facilities to retail and hospital customers across the MENA region. The Generics segment supplies oral and other non-injectable generic and specialty products to the United States retail market, leveraging its manufacturing facility in Columbus, Ohio.
- Revenue in GBP (TTM)2.40bn
- Net income in GBP226.44m
- Incorporated2005
- Employees8.97k
- LocationHikma Pharmaceuticals PLC1 New Burlington PlaceLONDON W1S 2HRUnited KingdomGBR
- Phone+44 207 399 2760
- Fax+44 207 399 2761
- Websitehttps://www.hikma.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Axsome Therapeutics Inc | 268.85m | -247.00m | 3.74bn | 545.00 | -- | 51.20 | -- | 13.93 | -6.54 | -6.54 | 7.11 | 1.92 | 0.5824 | 2.49 | 3.34 | 621,022.00 | -53.51 | -64.55 | -73.04 | -82.23 | 91.09 | -- | -91.87 | -227.05 | 2.37 | -60.51 | 0.6648 | -- | 440.80 | -- | -27.84 | -- | 77.86 | -- |
| IPCA Laboratories Ltd | 802.18m | 62.15m | 3.75bn | 17.34k | 60.37 | 5.96 | 37.42 | 4.68 | 26.07 | 26.07 | 336.37 | 264.10 | 0.7483 | 1.12 | 4.78 | 4,922,642.00 | 5.88 | 10.33 | 9.00 | 13.52 | 67.36 | 59.16 | 7.85 | 12.25 | 1.32 | 25.33 | 0.129 | 12.86 | 23.39 | 15.35 | 16.13 | 4.24 | 17.90 | 21.67 |
| GlaxoSmithKline Pharmaceuticals Limited | 334.70m | 63.46m | 3.77bn | 3.21k | 59.84 | 24.00 | 53.99 | 11.27 | 39.60 | 39.60 | 209.31 | 98.74 | 1.01 | 2.59 | 14.85 | 11,088,370.00 | 19.24 | 11.01 | 36.09 | 17.88 | 61.70 | 55.77 | 18.96 | 12.25 | 1.38 | 554.80 | 0.0088 | 192.07 | 6.21 | 2.00 | -2.91 | 5.78 | -36.02 | 9.86 |
| Krka d.d. Novo Mesto | 1.58bn | 299.39m | 3.78bn | 11.75k | 11.87 | 1.95 | 9.98 | 2.39 | 11.67 | 11.67 | 61.64 | 71.04 | 0.6951 | 1.35 | 3.87 | 162,896.80 | 13.14 | 12.64 | 15.77 | 15.12 | 56.55 | 57.29 | 18.90 | 18.71 | 2.47 | -- | 0.0057 | 59.21 | 5.18 | 6.28 | -13.58 | 12.45 | 8.35 | 18.57 |
| Glenmark Pharmaceuticals Ltd | 1.15bn | -95.73m | 3.89bn | 14.99k | -- | 4.90 | -- | 3.38 | -36.13 | -31.05 | 434.11 | 299.29 | 0.6951 | 1.53 | 4.04 | 8,171,082.00 | -5.64 | 1.02 | -8.51 | 1.43 | 65.64 | 59.47 | -8.11 | 1.43 | 1.00 | 2.56 | 0.1741 | 56.98 | 1.98 | 3.67 | -1,018.93 | -- | -5.89 | 4.56 |
| ADMA Biologics Inc | 304.08m | 54.12m | 4.00bn | 624.00 | 77.08 | 21.71 | 65.95 | 13.15 | 0.2763 | 0.2763 | 1.61 | 0.981 | 1.04 | 1.17 | 9.40 | 613,475.40 | 18.42 | -24.80 | 20.87 | -28.00 | 48.93 | 17.40 | 17.80 | -51.31 | 3.26 | 7.58 | 0.3041 | -- | 67.59 | 72.34 | 57.15 | -- | 18.91 | -- |
| Avidity Biosciences Inc | 8.04m | -222.80m | 4.03bn | 253.00 | -- | 3.37 | -- | 501.91 | -2.90 | -2.90 | 0.1028 | 12.64 | 0.0091 | -- | -- | 39,988.14 | -25.34 | -31.61 | -27.05 | -34.45 | -- | -- | -2,772.45 | -1,540.50 | -- | -- | 0.00 | -- | 3.64 | 90.71 | -21.97 | -- | 143.89 | -- |
| Richter Gedeon Vegyeszeti Gyar Nyrt | 1.64bn | 463.54m | 4.08bn | 11.60k | 8.66 | 1.68 | 7.25 | 2.48 | 1,248.46 | 1,248.46 | 4,419.54 | 6,425.20 | 0.5959 | 1.36 | 3.77 | 69,931,480.00 | 16.92 | 11.64 | 19.01 | 13.28 | 68.64 | 58.18 | 28.40 | 18.93 | 2.03 | -- | 0.0454 | 39.94 | 0.2993 | 12.57 | -6.05 | 35.06 | 15.59 | 33.94 |
| Hikma Pharmaceuticals Plc | 2.40bn | 226.44m | 4.17bn | 8.97k | 18.57 | 2.29 | 10.92 | 1.74 | 1.01 | 1.01 | 10.74 | 8.22 | 0.6374 | 1.77 | 3.38 | 267,324.30 | 6.13 | 8.19 | 8.47 | 11.30 | 47.40 | 50.29 | 9.61 | 13.77 | 0.9775 | 7.81 | 0.3568 | 36.71 | 14.22 | 6.73 | 1.06 | -7.59 | 7.97 | 14.03 |
| Humanwell Healthcare Group Co Ltd | 2.80bn | 214.62m | 4.26bn | 17.68k | 19.64 | 2.17 | -- | 1.52 | 1.21 | 1.21 | 15.87 | 10.95 | 0.6902 | 3.80 | 2.74 | 1,445,825.00 | 7.13 | 6.20 | 13.12 | 12.72 | 45.59 | 42.82 | 10.33 | 9.84 | 1.21 | 12.09 | 0.3171 | 18.87 | 9.79 | 5.65 | -14.07 | -- | 8.25 | -- |
| Siegfried Holding AG | 1.15bn | 114.88m | 4.46bn | 3.80k | 36.96 | 5.22 | 23.24 | 3.88 | 29.87 | 29.87 | 299.09 | 211.39 | 0.7046 | 2.00 | 3.80 | 326,556.30 | 7.06 | 6.51 | 8.64 | 7.98 | 25.87 | 23.24 | 10.03 | 9.06 | 1.40 | 14.34 | 0.3217 | 15.26 | 3.41 | 9.87 | -28.16 | 18.34 | 17.95 | 6.72 |
| Ono Pharmaceutical Co Ltd | 2.49bn | 488.97m | 4.48bn | 3.85k | 8.68 | 1.05 | 7.69 | 1.80 | 201.26 | 201.26 | 1,026.05 | 1,665.85 | 0.4987 | 2.37 | 3.47 | 125,694,000.00 | 9.80 | 11.95 | 11.16 | 13.73 | 75.38 | 74.11 | 19.65 | 23.89 | 2.80 | -- | 0.1702 | 32.25 | 12.41 | 11.73 | 13.53 | 19.95 | -6.79 | 12.20 |
Data as of Nov 22 2024. Currency figures normalised to Hikma Pharmaceuticals PLC's reporting currency: UK Pound GBX
25.37%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Wellington Management Co. LLPas of 31 Dec 2023 | 11.56m | 5.21% |
| JPMorgan International Bank Ltd.as of 01 Nov 2024 | 10.75m | 4.84% |
| Capital Research & Management Co. (World Investors)as of 01 Nov 2024 | 6.93m | 3.12% |
| BlackRock Advisors (UK) Ltd.as of 31 Dec 2023 | 6.15m | 2.77% |
| Mawer Investment Management Ltd.as of 30 Jun 2024 | 4.86m | 2.19% |
| The Vanguard Group, Inc.as of 01 Nov 2024 | 4.23m | 1.90% |
| Royal London Asset Management Ltd.as of 01 Nov 2024 | 3.14m | 1.41% |
| Polar Capital LLPas of 30 Sep 2024 | 3.06m | 1.38% |
| Threadneedle Asset Management Ltd.as of 31 Aug 2024 | 3.01m | 1.36% |
| Norges Bank Investment Managementas of 01 Nov 2024 | 2.62m | 1.18% |
More ▼
Data from 30 Jun 2024 - 01 Nov 2024Source: FactSet Research Systems Inc.
